Subscriber Authentication Point
lvrea
Home All issues Volume 25 / No 4 (Juillet 2016) Réanimation, 25 4 (2016) 400-407 References
Free Access
Issue
Réanimation
Volume 25, Number 4, Juillet 2016
Médecine interne et transversalité
Page(s) 400 - 407
Section Mise au Point / Update
DOI https://doi.org/10.1007/s13546-016-1209-4
Published online 08 June 2016
  • Banerji A, Clark S, Blanda M, et al (2008) Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 100:327–32 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Hardt J, Schicketanz KH, Ressel N (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229–35 [CrossRef] [PubMed] [Google Scholar]
  • Fremeaux-Bacchi V, Guinnepain MT, Cacoub P, et al (2002) Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type II. Am J Med 113:194–9 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Aberer W, Banerji A, et al (2014) Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69:602–16 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Siedlecki K, Bosch S, et al (2000) Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 75:349–54 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Staubach P, Eckardt AJ, Hardt J (2006) Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 101:619–27 [CrossRef] [PubMed] [Google Scholar]
  • Guichon C, Floccard B, Coppere B, et al (2011) One hypovolaemic shock… two kinin pathway abnormalities. Intensive Care Med 37:1227–8 [CrossRef] [PubMed] [Google Scholar]
  • Zuraw BL (2008) Clinical practice. Hereditary angioedema. N Engl J Med 359:1027–36 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Bork K, Caballero T, et al (2012) Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67:147–57 [CrossRef] [PubMed] [Google Scholar]
  • Longhurst H, Cicardi M (2012) Hereditary angio-oedema. Lancet 379:474–81 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Gompel A, Bouillet L, et al (2015) Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Ann Allergy Asthma Immunol 114:499–503 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Hardt J, Witzke G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130:692–7 [CrossRef] [PubMed] [Google Scholar]
  • Craig TJ, Bewtra AK, Bahna SL, et al (2011) C1 esterase inhibitor concentrate in 1,085 hereditary angioedema attacks — final results of the IMPACT 2 study. Allergy 66:1604–11 [CrossRef] [PubMed] [Google Scholar]
  • Bowen T, Cicardi M, Farkas H, et al (2010) 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Zingale LC, Bergamaschini L, Agostoni A (2004) Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 164:910–3 [CrossRef] [PubMed] [Google Scholar]
  • Kostis JB, Kim HJ, Rusnak J, et al (2005) Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165:1637–42 [CrossRef] [PubMed] [Google Scholar]
  • Miller DR, Oliveria SA, Berlowitz DR, et al (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624–30 [CrossRef] [PubMed] [Google Scholar]
  • Pfeffer MA, McMurray JJ, Velazquez EJ, et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–906 [CrossRef] [PubMed] [Google Scholar]
  • Haymore BR, Yoon J, Mikita CP, et al (2008) Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 101:495–9 [CrossRef] [PubMed] [Google Scholar]
  • Blacher J, Halimi JM, Hanon O, et al (2014) Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol 28:1–9 [CrossRef] [Google Scholar]
  • Marant C, Romon I, Fosse S, et al (2008) French medical practice in type II diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab 34:38–45 [CrossRef] [PubMed] [Google Scholar]
  • Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al (1994) Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90:583–612 [CrossRef] [PubMed] [Google Scholar]
  • Bluestein HM, Hoover TA, Banerji AS, et al (2009) Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol 103:502–7 [CrossRef] [PubMed] [Google Scholar]
  • Brown NJ, Byiers S, Carr D, et al (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54:516–23 [CrossRef] [PubMed] [Google Scholar]
  • Duerr M, Glander P, Diekmann F, et al (2010) Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 5:703–8 [CrossRef] [PubMed] [Google Scholar]
  • Bova M, Guilarte M, Sala-Cunill A, et al (2015) Treatment of ACEI-related angioedema with icatibant: a case series. Intern Emerg Med 10:345–50 [CrossRef] [PubMed] [Google Scholar]
  • Baş M, Greve J, Stelter K, et al (2015) A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372:418–25 [CrossRef] [PubMed] [Google Scholar]
  • Roberts JR, Lee JJ, Marthers DA (2012) Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic. Am J Cardiol 109:774–5 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Achamlal J, Reuter PG, et al (2015) Angioedema related to angiotensin-converting enzyme inhibitors: attack severity, treatment, and hospital admission in a prospective multicenter study. Medicine (Baltimore) 94:e1939 [CrossRef] [PubMed] [Google Scholar]
  • Dean DE, Schultz DL, Powers RH (2001) Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 46:1239–43 [PubMed] [Google Scholar]
  • Wilson DA, Bork K, Shea EP, et al (2010) Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 104:314–20.e2 [CrossRef] [PubMed] [Google Scholar]
  • Aygören-Pürsün E, Bygum A, Beusterien K, et al (2014) Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis 9:99 [CrossRef] [PubMed] [Google Scholar]
  • Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, et al (2010) Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 203:131.e1–7 [CrossRef] [Google Scholar]
  • Bouillet L, Lehmann A, Gompel A, et al (2015) Hereditary angiœdema treatments: recommendations from the French National Center for Angiœdema (Bordeaux consensus 2014). Presse Med 44:526–32 [CrossRef] [PubMed] [Google Scholar]
  • Zuraw BL, Busse PJ, White M, et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513–22 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Banerji A, Bracho F, et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532–41 [CrossRef] [PubMed] [Google Scholar]
  • Bork K (2010) Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 6:15 [CrossRef] [PubMed] [Google Scholar]
  • Wintenberger C, Boccon-Gibod I, Launay D, et al (2014) Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178:112–7 [CrossRef] [Google Scholar]
  • Nielsen EW, Gramstad S (2006) Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 50:120–2 [CrossRef] [PubMed] [Google Scholar]
  • Rasmussen ER, Bygum A (2013) ACE-inhibitor induced angio-oedema treated with complement C1 inhibitor concentrate. BMJ Case Rep pii: bcr2013200652 [Google Scholar]
  • Nosbaum A, Bouillet L, Floccard B, et al (2013) Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema. Rev Med Interne 34:209–13 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Karami A, Stirnemann J, et al (2013) Bradykinin-mediated angioedema: factors prompting ED visits. Am J Emerg Med 31:124–9 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Lapostolle F, Sapir D, et al (2013) The early treatment of bradykinin angioedema, a challenge for emergency medicine. Eur J Emerg Med 20:291–2 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.